Cloud-based technology has enabled a healthcare provider to rapidly transition to new cancer treatment guidelines.
The private Seventh-day Adventist Hospital Sydney (San) in Sydney’s north was an early adopter of Cancer Institute NSW guidelines on anticancer drug dosing in kidney dysfunction (ADDIKD).
First published in 2022, the eviQ evidence-based guideline standardizes the measurement of kidney dysfunction to provide more tailored dosing recommendations compared to current calculation methods. Have.
CHALLENGES
The transition to this guideline poses a significant change management challenge for the San, the largest private cancer center in New South Wales: in addition to treating cancer, it also offers a range of treatments. Other daytime treatments, such as blood transfusions, immune globulin infusions, and non-cancer treatments. immunomodulatory therapies and iron infusions, among others. It has grown to accommodate more than 17,000 patient visits per year.
It is believed that switching to a new or updated cancer treatment regimen is often tedious; San has previously relied on manual screening to detect patients with renal dysfunction for whom the Cockcroft-Gault method is not appropriate, and clinicians and pharmacists must calculate and compare treatment Manually adjust the dose for their patients.
PROPOSE
Because the hospital registered to treat cancer patients several months in advance, the hospital’s process management working group decided to take a two-pronged approach in applying the ADDIKD guidelines while also leveraging the platform. cloud-based medical oncology and management by SaaS healthcare provider EpiSoft.
MEETING THE CHALLENGE
While pharmacists and clinicians re-evaluate dosing decisions for incoming patients, taking into account the doses calculated according to EpiSoft recommendations, treatment protocols are also being upgraded for new patients through a “rigorous” approval process.
Follow to health IT provider.
RESULT
Through EpiSoft’s cancer management system, much of the workload during the conversion to San’s ADDIKD guidelines was significantly reduced – it imports the eGFR pathology results used to calculate the carboplatin dose in near real time and allows clinicians to quickly compare Cockcroft-Gault and dose calculate eGFR (Estimated Glomerular Filtration Rate). The system also replicates dosing decisions for all future cycles of care and is reviewed periodically.
“The integration of EpiSoft with eviQ and the ADDIKD guidance made the transition possible in a short timeframe at the center,” attested to Lily Chong, project pharmacist and EpiSoft system administrator for San. our busy cancer center.”
